To The Moon

Xpeng <9868.HK>:Announces Vehicle Delivery Results For March And First Quarter 2023.In March 2023, Xpeng Delivered 7,002 Smart Evs, Representing A 17% Increase Over Prior Month.Total Deliveries For Q1 Of 2023 Reached 18,230 Vehicles..A Total Of 3,030 P7 Series Sedans Were Delivered In March, Representing A 32% Increase Month-Over-Month..

Prairie Provident Resources Inc :Prairie Provident Resources Announces Fourth Quarter And Year-End 2022 Financial And Operating Results And Update On Repositioning Plan.Production Averaged 3,753 Boe/D (64% Liquids) For Q4 Of 2022, A 14% Decrease From Same Period In 2021.

Ams Osram Ag :Eqs-News: Ams-Osram Ag: Aldo Kamper Officially Joins Ams Osram As Ceo.Aldo Kamper Has Been Appointed Ceo Of Ams Osram Group Subsidiary Osram Licht Ag As Of 1 April 2023.Aldo Kamper Also Assumes Role Of Ceo Of Osram Licht Ag, Which Is A Subsidiary Of Ams Osram Group.

AUROBINDO PHARMA: CO TRANSFER IT'S UNIT CONSTITUTING ANTIBIOTIC API DIVISION TO SUBSIDIARY CO FOR CASH CONSIDERATION OF 503CR RUPEES

Gatos Silver Inc :Gatos Silver Explains Delay In Filing 2022 Year-End Financial Statements And Announces Restatement Of Previously Issued Financial Statements For Non-Cash Adjustments.Gatos Silver

Clearone Inc :Fy Gaap Earnings Per Share $0.83 .Clearone, Inc. Reports Fourth Quarter 2022 Financial Results.Q3 Loss Per Share $0.05.Q4 2022 Revenue Was $4.0 Million, Compared To $7.2 Million In Q4 2021.Q4 Non-Gaap Diluted Loss Per Share $0.09.Q4 Diluted Income Per Share $0.97.Delay In Transition Is Expected To Affect Our 2023-Q1 Revenues.

ClearOne 4Q Adj Loss/Shr 9c >CLRO

Deep Medicine Acquisition Corp :. And Trugolf, Inc. Announce The Execution Of A Definitive Merger Agreement.Business Combination With Deep Medicine Acquisition Corp. Values Trugolf'S At An Implied Enterprise Value Of $125 Million.Christopher Jones, Ceo And Chairman Of Trugolf, And Existing Management Team Will Lead Merged Company.Deep Medicine Acquisition

Intercure Ltd :Intercure Announces Record Fourth Quarter And Fiscal Year End 2022 Results.Qtrly Revenue C$41 Million (Nis 106 Million) 33% Growth Yoy.

KORE: Provides Additional Details Relating to Anticipated Filing of Its Annual Report on Form 10-K for Fiscal Yr 2022

KORE: Confirms No Changes in Rev or Adjusted EBITDA for 4Q and Yr Ending 2022, All as Reported in 'KORE Reports Preliminary and Unaudited 4Q and Full-Yr 2022 Results; Provides Full-Yr 2023 Rev Guidance of $300 to $310 M, Representing Yr-Over-Yr Growth of 12% to 15%,' Issued March 27 >KORE

KORE: Will File the 10-K as Soon as Practicable, Expected No Later Than April 7 >KORE

KORE: Delay in Filing the 10-K Is Not Due to Any Disagreement With the Company's Independent Registered Public Acctg Firm >KORE

Delta 9 Cannabis 4Q Loss/Shr C$0.09 >DN.T

Delta 9 Cannabis 4Q Loss C$11.2M >DN.T